Evaluation of Dendritic Cell Products Generated for Human Therapy and Post-Treatment Immune Monitoring - - BioPharm International


Evaluation of Dendritic Cell Products Generated for Human Therapy and Post-Treatment Immune Monitoring

BioPharm International
Volume 21, Issue 3

Table 3. Assays for functional evaluation of dendritic cell products*
Functional assays. A variety of functional assays for newly generated DC products are available (Table 3). One popular assay is the mixed lymphocyte reaction (MLR), in which allogeneic T cells serve as responders and DCs—titered into the co-culture at various T cell–DC ratios—serve as stimulators.29 The assay measures levels of T-cell responses to alloantigens presented by DCs, and is not directly relevant to the response elicited by tumor antigens. A requirement for the panel of T cells that can recognize a variety of HLA specificities represents a considerable practical limitation for a routine use of this assay. Therefore, flow cytometry-based assays have largely replaced MLR for functional assessments of DCs. Among these, endocytosis of FITC-labeled dextran 30 combined with measurement of mannose receptor expression with anti-CD206 antibody is often used.25 This assay measures an entirely different function of DCs, one that is essential for antigen uptake and that potentially discriminates between a receptor-mediated antigen internalization versus endocytosis. These two pathways of antigen uptake may have different consequences for antigen processing and presentation.31 Therefore, it might be important to determine their use by tumor-derived antigens relative to the type of T-cell response these antigens elicit in vivo.

Flow cytometry assays for DCs. Flow cytometry-based assays measure the state of DC maturation. After five to six days of culture, immature DCs are CD40+, CD80+, CD86+, and HLA-DR+, but have low expression levels of CD83. Upon maturation, DCs typically express higher levels of HLA molecules and co-stimulatory molecules (CD80, CD83, and CD86), in addition to enhanced expression of the chemokine receptor, CCR7. The presence of CD206 (the mannose receptor) and absence of CD14 (a monocyte marker) on the DC surface may be helpful for defining the state of DC differentiation. Of the utmost importance is full ex vivo activation of DCs, which can be achieved by various approaches (e.g., combinations of cytokines, toll-receptor ligands, or the CD40 ligand) and can be evaluated by upregulation of surface markers and by functional assays.

More recently, methods able to quantitate expression levels of Class I and Class II major histocompatibility complex (MHC) molecules, ICAM, or individual components of APM have been introduced to assess DCs' potential for T-cell stimulation.32 These flow-based assays proved to be quite informative, as DCs derived from monocytes of patients with cancer were shown to have aberrant expression of APM components, which was related to inadequate T-cell stimulation, at least in vitro. 32 The ability to evaluate DC-mediated Th1/Th2 polarization (e.g., expression of interferon (IFN)-gamma or IL-4) following co-culture of purified CD3+CD45RA+ lymphocytes with DC and re-stimulation with PMA/ionomycin also has been used in some studies.33

Measuring co-stimulatory capacity. In addition to processing antigens and presenting individual epitopes to epitope-specific T cells, DCs exhibit a strong co-stimulatory capacity, which is much higher than that of other cells. In fact, expression of co-stimulatory molecules on DC has been used as a surrogate marker for their functional potential.34 Because co-stimulation plays a critical role in the induction of tumor-specific immunity, this assay may be relevant to the ability of DCs to function in stimulating T cells specific for tumor antigens. As such, the assay for co-stimulatory molecule expression, called the costimulatory (COSTIM) assay, might be especially useful in assessing the functional potential of ex vivo-generated DCs in anticancer vaccines. It has been reported to work with both allogeneic and autologous DC products.35

General remarks on DC release criteria. While the various functional assays listed in Table 3 provide useful information about DC properties, none has been validated as a tool for measuring the potency of DCs generated for human therapy. These assays might be standardized, but a formal validation would require establishing a correlation with the in vivo performance of the cells. It appears that none of the listed assays has been correlated with the clinical efficacy of the administered DC products. Nevertheless, the availability of several assays that measure diverse DC functions provides an opportunity for an improved control of the variability of DC products and for establishing a clinically meaningful functional profile for DCs. A functional DC profile based on results of these assays is likely to give a more reliable estimate of DCs' therapeutic potential than any single assay and may prove to be a better surrogate of their clinical efficacy.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here